StockData
HUTCHMED (China) Ltd logo

HUTCHMED (China) Ltd (HCM) stock

HCMNasdaqPharmaceutical PreparationsAlso trades as HMDCF
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 5, 2026Score 5/30
$13.99−0.41 (-2.85%)

Close on Nov 18, 2026Market cap $2.44BP/E 5.4Yield –

HUTCHMED (China) operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

HUTCHMED (China)'s operating income for the twelve months ending Dec 31, 2019 was -$146.39M. For fiscal 2025 it was -$39.16M. The highest annual figure on record is $18.38M in fiscal 2023.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$39.16M–
FY2024Dec 31, 2024-$43.71M-337.9%
FY2023Dec 31, 2023$18.38M–
FY2022Dec 31, 2022-$407.69M–
FY2021Dec 31, 2021-$328.32M–
FY2020Dec 31, 2020-$196.67M–
FY2019Dec 31, 2019-$146.39M–
FY2018Dec 31, 2018-$92.64M–
FY2017Dec 31, 2017-$53.42M–
FY2016Dec 31, 2016-$46.70M–
FY2015Dec 31, 2015-$9.77M–
FY2014Dec 31, 2014-$18.26M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2019Dec 31, 2019-$38.43M–
Q3 FY2019Sep 30, 2019-$35.94M–
Q2 FY2019Jun 30, 2019-$35.96M–
Q1 FY2019Mar 31, 2019-$36.05M–
Q4 FY2018Dec 31, 2018-$24.17M–
Q3 FY2018Sep 30, 2018-$14.79M–
Q2 FY2018Jun 30, 2018-$28.66M–
Q1 FY2018Mar 31, 2018-$25.02M–

More HUTCHMED (China) figures

See a number that looks wrong?